Benjamin Quintana, MD
Endocrinology, Diabetes & Metabolism · Bethlehem, PANPI 1265522585
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $129,760 of the $151,487 with a category attached, or 85.7%. 22 manufacturers reported payments, led by AstraZeneca at 29.3% of the total. Reporting peaked in 2019 at $40,398 and has fallen 91.7% since, to $3,362 in 2025. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $425.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$44K
- Boehringer Ingelheim$39K
- Novo Nordisk$37K
- Lilly USA, LLC$25K
- Dexcom, Inc.$2K
- Medtronic$2K
- plus $3K from 16 others
What the payments were for
- Consulting fees$3,6562%
- Speaking & faculty fees$129,76086%
- Travel & lodging$5,5814%
- Food & beverage$12,4338%
- Education$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 76 | $44,323 |
| Boehringer Ingelheim | 74 | $38,986 |
| Novo Nordisk | 45 | $36,834 |
| Lilly USA, LLC | 58 | $24,842 |
| Dexcom, Inc. | 2 | $1,791 |
| Medtronic(2 entities) | 26 | $1,581 |
| Biotronik Inc. | 13 | $826 |
| Abbott | 23 | $449 |
| AbbVie | 3 | $349 |
| Amgen(2 entities) | 3 | $240 |
| Johnson & Johnson | 4 | $224 |
| Insulet Corporation | 3 | $213 |
| Tandem Diabetes Care, Inc. | 4 | $189 |
| Xeris Pharmaceuticals, Inc. | 3 | $165 |
| Sequel Med Tech, LLC | 1 | $134 |
| OPKO Pharmaceuticals, LLC | 8 | $132 |
| Mannkind Corporation | 3 | $64 |
| Embecta Corp. | 2 | $48 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| BD | 1 | $25 |
| Halozyme Inc | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$61,750
- FARXIGA$42,688
- RYBELSUS$20,803
- Ozempic$7,250
- DEXCOM CGM$1,791
- MINIMED 780G$468
- Synthroid$250
- InPen$157
- TWIIST$134
- EVENITY$125
- FreeStyle Libre Pro$125
- Rayaldee$125
- MOUNJARO$125
- GVOKE PFS$124
- Enlite Sensor$110
- Minimed 770G System$108
- Omnipod$108
- Minimed 670G System$106
- Repatha$100
How this compares
$151,487 in reported general payments places this provider in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 391 | $468,025 |
| JardianceEmpagliflozin | 273 | $298,874 |
| MounjaroTirzepatide | 236 | $264,829 |
| TrulicityDulaglutide | 186 | $253,899 |
| TradjentaLinagliptin | 143 | $143,519 |
| FarxigaDapagliflozin Propanediol | 88 | $124,057 |
| JanuviaSitagliptin Phosphate | 62 | $68,551 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $57,640 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 285 | $43,414 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $37,275 |
| Humalog Kwikpen U-200Insulin Lispro | 18 | $34,485 |
| Humalog Kwikpen U-100Insulin Lispro | 112 | $33,809 |
| Tresiba Flextouch U-100Insulin Degludec | 57 | $33,074 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 40 | $31,788 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 72 | $29,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi | $24,842 | $539,442477 claims |
| Novo NordiskOzempic, Novolog | $36,834 | $490,031444 claims |
| Boehringer IngelheimJardiance, Tradjenta | $38,986 | $442,393416 claims |
| AstraZenecaFarxiga | $44,323 | $124,05788 claims |
| AbbVieSynthroid | $349 | $6,533104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Bethlehem
- Maria LamotheBethlehem$40K
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.